Royalty Pharma plc(RPRX)

NASDAQ Global Select
Sector: Healthcare | Industry: Biotechnology
Royalty Pharma plc logo

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Latest News & Analysis

Royalty Pharma (RPRX) analysis: leadership changes, key investments in Biogen's Litifilimab, and market resilience strategies.
Apr 9, 2025

Royalty Pharma (RPRX): Leadership, Investments, and Market View

Royalty Pharma navigates the biopharma royalty space with new leadership, strategic investments, and a resilient healthcare sector position. Investor Day insights ahead.

Read more →
Royalty Pharma: Investing in biopharma innovation, R&D collaborations, and strategic portfolio management for long-term shareholder value and growth.
Mar 27, 2025

Royalty Pharma (RPRX): Investor Day, Biogen & Portfolio Strategy

Analysis of Royalty Pharma (RPRX): Upcoming Investor Day, Biogen collaboration impact, portfolio strategy, and financial health. Insights for investors.

Read more →
Royalty Pharma: Strategic investments, growth, and dividends in the biopharmaceutical royalty space. Financial performance and shareholder value analysis.
Mar 3, 2025

Royalty Pharma (RPRX): Growth, Dividends, and Strategic Investments

Royalty Pharma (RPRX) navigates growth via strategic investments and shareholder returns. Recent collaborations, bond monetization, and dividend hikes underscore its approach.

Read more →
Royalty Pharma: Strategic investments in biopharmaceutical royalties, driving growth and shareholder value in a dynamic market. Q4 2024 analysis and future outlook.
Feb 28, 2025

Royalty Pharma (RPRX): Strategic Growth, Biogen Collaboration, and Shareholder Value

Royalty Pharma (RPRX) navigates the biopharmaceutical landscape through strategic capital allocation, R&D collaborations, and shareholder value initiatives. Recent Q4 results and the Biogen collaboration underscore its growth commitment.

Read more →
Royalty Pharma (RPRX) Q4 2024 Results: Financial performance, Biogen collaboration, and strategic growth initiatives.
Feb 26, 2025

Royalty Pharma (RPRX): Q4 2024 Results, Biogen Collaboration, and Growth Outlook

Royalty Pharma (RPRX) Q4 2024 results showcase strong financials and strategic investments, including a Biogen collaboration and dividend increase. A deep dive into growth and outlook.

Read more →
Royalty Pharma (RPRX) Q4 2024 financial analysis, strategic investments, and future outlook.
Feb 25, 2025

Royalty Pharma (RPRX) Q4 2024: Financial Analysis and Future Outlook

Royalty Pharma (RPRX) demonstrates strong Q4 2024 performance, strategic investments, and commitment to shareholder value. Analyst consensus points to a positive outlook.

Read more →